Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in COVID-19
NCT04380402Phase 2Unknown
- Sponsor
- Mount Auburn Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mount Auburn Hospital. Primary endpoint: Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death at 30 days. Status: unknown.
02
Drugs
atorvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380402.